Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.

There is gain in loss.

wallstreetcnDec 24 21:26 ET

WUXI APPTEC will transfer the WuXi ATU Business to a USA Fund. Is the "optimal solution" for the "gray rhino" of the Biological Safety Act?

① This evening, WUXI APPTEC announced that it will transfer its WuXi ATU Business in the USA and United Kingdom to the USA Private Equity Fund Altaris in exchange for Cash.; ② In the first three quarters, WuXi ATU achieved revenue of 0.853 billion, accounting for only about 3% of the total revenue for the first three quarters.; ③ After the transfer of this Business, the accusations and suspicions related to its gene business may be cleared under the Biosecurity Act.

cls.cnDec 24 10:58 ET

A total scale of 30 billion! The first national-level mother fund in the foreign trade and economic field is being raised, introducing listed company LP Jinbo Bio and Joinn Laboratories.

① The Innovation and Development Guidance Fund for Service Trade is a national-level fund initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, approved by the State Council, with a total scale of 30 billion yuan. ② An IR practitioner stated to the Star Daily that the second phase of the service trade fund inviting listed companies to become LPs may be a more market-oriented signal.

cls.cnDec 13 05:33 ET

When will Hunan Nucien Pharmaceutical Co., Ltd. emerge from the shadow of losses after the termination and delay of core Innovative Drugs projects?

① Due to the high difficulty and slow progress of research and development, Hunan Nucien Pharmaceutical Co., Ltd. has terminated the development of the paramivir powder inhalation project. Additionally, due to stricter approval processes, the paramivir inhalation solution project will be postponed for two years. ② In the face of competition for paramivir injection, the adjustment of new drug projects will bring new uncertainties to the development of Hunan Nucien Pharmaceutical Co., Ltd.

cls.cnDec 12 03:11 ET

0.15 billion! Wuxi AppTec invested in a French VC, adding to the European biomedical market.

① Wuxi Apptec plans to invest in the "Jeito II S.L.P." fund, with a total target scale not exceeding 1.2 billion euros, and the fund is expected to invest in 14-17 medical innovative startups. ② Previously, Wuxi Apptec planned to invest 10 million euros in another well-known biotechnology investment institution in Europe, focusing on early-stage biomedical companies in Europe.

cls.cnDec 9 05:34 ET

Intense competition in CRO has reduced gross margin. Sunlight Nuohe is entering the animal health field to seek new growth points.

① Sunshine Nuohuo has experienced growth in revenue and net income in the first three quarters of this year compared to previous years, but intense competition in the industry has led to a decline in gross margin, and the chairman revealed that the company is increasing its investment in research and development. ② To seek new growth points, Sunshine Nuohuo is expanding its CRO business from the human pharmaceutical field to the animal health field by establishing subsidiaries, and has signed service orders with several medium and large animal pharmaceutical companies.

cls.cnDec 2 02:59 ET